105 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
lease liability - long-term, net of current portion
Warrant liability - long term
Total liabilities
Total stockholders' equity
Total liabilities
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
22 Feb 24
Regulation FD Disclosure
9:30am
.
Unfortunately, effective treatment options are limited and only 29% of people diagnosed survive beyond 5 years. In order to improve this overall long-term survival … for a bone marrow transplant or achieving long-term remission.
Similarly, bone marrow transplants are successful in as many as 80% of these eligible
424B3
1xshfi0
16 Feb 24
Prospectus supplement
5:19pm
8-K
EX-10.2
4r6l9
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
sw9hm1m kml8j6g0o
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
94kgel4vag
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
m7y56vasf4bl9
11 Aug 23
Moleculin Reports Second Quarter 2023 Financial Results
7:00am
S-8
EX-4.5
6kk23 d16q79d19msl
21 Jun 23
Registration of securities for employees
5:16pm
DEFA14A
sai92i75
7 Jun 23
Additional proxy soliciting materials
5:00pm
DEFA14A
3qfanjl bocmb8lm
30 May 23
Additional proxy soliciting materials
7:48am
8-K
EX-99.1
xves jl6mr59v
11 May 23
Moleculin Reports First Quarter 2023 Financial Results
7:05am